An artificial intelligence-powered precision cardiovascular medicine company named Cardio Diagnostics has launched a first-of-its-kind platform called Actionable Clinical Intelligence or ACI, that offers new epigenetic and genetic insights to clinicians prescribing the company’s Epi+Gen CHD and PrecisionCHD tests.
Epi+Gen CHD is a powerful test that predicts the three-year risk for a coronary heart disease (CHD) event – a heart attack – and PrecisionCHD is a test for the detection of CHD. These AI-powered integrated genetic-epigenetic clinical tests only require a simple blood draw that can be performed at home or in provider settings without the need to wait weeks or months to get tested.
Epi+Gen CHD is a powerful test that predicts the three-year risk for a coronary heart disease (CHD) event – a heart attack – and PrecisionCHD is a test for the detection of CHD. These AI-powered integrated genetic-epigenetic clinical tests only require a simple blood draw that can be performed at home or in provider settings without the need to wait weeks or months to get tested.
Category
🗞
NewsTranscript
00:00 An artificial intelligence-powered precision cardiovascular medicine company named CardioDiagnostics
00:06 has launched a first-of-its-kind platform called Actional Clinical Intelligence, or
00:10 ACI, that offers new epigenetic and genetic insights to clinicians prescribing the company's
00:15 EpiPlus Gen CHD and Precision CHD tests.
00:18 EpiPlus Gen CHD is a powerful test that predicts the three-year risk for a coronary heart disease
00:23 event, a heart attack, and Precision CHD is a test for the detection of CHD.
00:28 These AI-powered integrated genetic/epigenetic clinical tests only require a simple blood
00:32 draw that can be performed at home or in provider settings without the need to wait weeks or
00:36 months to get tested.
00:38 Results from both of these laboratory-developed tests are coupled to the ACI platform.
00:42 By merging LDT results with a patient's unique epigenetic and genetic biomarkers and
00:46 clinical information, ACI can provide deeper and actionable insights to clinicians about
00:51 factors driving the patient's CAD.
00:53 Heart disease imposes staggering costs on the U.S. healthcare system and workforce.
00:57 According to the CDC, heart disease results in $147 billion per year lost in productivity.
01:02 The condition leads to around 655,000 deaths annually, one in four of all deaths in the
01:07 U.S.
01:08 Given the widespread impact and high costs of heart disease, innovative solutions for
01:12 prevention and early detection can provide significant value.
01:15 For example, one study found that CardioDiagnostics' EpiPlus Gen CHD test for assessing coronary
01:20 heart disease risk could reduce costs by up to $42,000 per quality-adjusted life year
01:25 compared to standard testing.
01:27 With the ability to identify individuals at risk earlier and enable more personalized
01:30 treatment plans, the company's epigenetic and genetic testing paired with the actionable
01:35 clinical intelligence platform aims to help mitigate the effects of heart disease, potentially
01:39 saving lives and reducing strain on the healthcare system.
01:43 Widespread adoption of such innovative approaches has the potential to significantly reduce
01:46 the prevalence and consequences of heart disease nationwide.
01:49 "Many at risk for or who already have coronary heart disease do not have traditional risk
01:54 factors, signs, and symptoms," said Misha Dogen, Ph.D. and co-founder at CardioDiagnostics.
02:00 By harnessing the power of epigenetics, genetics, and AI, we now have the ability to personalize
02:04 the management and treatment of heart disease at the molecular level where biology happens.
02:09 That is the promise of precision cardiovascular medicine.
02:11 (upbeat music)